托珠单抗在 CAR-T 细胞治疗后严重胃肠道屏障损伤中的潜在作用。
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy.
机构信息
Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France.
CHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, France.
出版信息
J Microbiol Immunol Infect. 2021 Apr;54(2):327-330. doi: 10.1016/j.jmii.2021.02.006. Epub 2021 Feb 27.
We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.
我们报告了一例因抗 CD19 CAR T 细胞治疗后使用托珠单抗导致胃肠道黏膜修复延迟而引起的败血症和播散性念珠菌病。托珠单抗可能抑制了肠道组织修复，并促进了细菌易位，导致肠道黏膜被酵母菌侵袭，因为白细胞介素 6 已知参与黏膜伤口愈合。
Zotero 插件